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Abstract
Although immunoregulation of alloreactive human CTLs has been described, the direct influence of CD4
+ Tregs on CD8
+
cytotoxicity and the interactive mechanisms have not been well clarified. Therefore, human CD4
+CD127
2CD25
+FOXP3
+
Tregs were generated in MLR, immunoselected and their allospecific regulatory functions and associated mechanisms were
then tested using modified
51Chromium release assays (Micro-CML), MLRs and CFSE-based multi-fluorochrome flow
cytometry proliferation assays. It was observed that increased numbers of CD4
+CD127
2CD25
+FOXP3
+ cells were generated
after a 7 day MLR. After immunoselection for CD4
+CD127
2CD25
+ cells, they were designated as MLR-Tregs. When added as
third component modulators, MLR-Tregs inhibited the alloreactive proliferation of autologous PBMC in a concentration
dependent manner. The inhibition was quasi-antigen specific, in that the inhibition was non-specific at higher MLR-Treg
modulator doses, but non-specificity disappeared with lower numbers at which specific inhibition was still significant. When
tested in micro-CML assays CTL inhibition occurred with PBMC and purified CD8
+ responders. However, antigen specificity
of CTL inhibition was observed only with unpurified PBMC responders and not with purified CD8
+ responders or even with
CD8
+ responders plus Non-T ‘‘APC’’. However, allospecificity of CTL regulation was restored when autologous purified CD4
+
T cells were added to the CD8
+ responders. Proliferation of CD8
+ cells was suppressed by MLR-Tregs in the presence or
absence of IL-2. Inhibition by MLR-Tregs was mediated through down-regulation of intracellular perforin, granzyme B and
membrane-bound CD25 molecules on the responding CD8
+ cells. Therefore, it was concluded that human
CD4
+CD127
2CD25
+FOXP3
+ MLR-Tregs down-regulate alloreactive cytotoxic responses. Regulatory allospecificity, however,
requires the presence of cognate responding CD4
+ T cells. CD8
+ CTL regulatory mechanisms include impaired proliferation,
reduced expression of cytolytic molecules and CD25
+ activation epitopes.
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Introduction
CD4
+ regulatory T cells (Tregs) are proposed to play a key role in
the generation and maintenance of tolerance to organ and tissue
allotransplants [1,2,3]. Experiments in rodent models have shown
regulatory effects on cytotoxic T cells (CTLs) by CD4
+ Tregs [4,5].
In humans, CD4
+ Tregs have been demonstrated to impair CTL
function in the settings of cancer [6], and chronic viral diseases
[7,8,9,10]. CD8
+ cytotoxic T lymphocytes (CTLs) can also be
demonstrated post-transplantation even in patients who have stable
graft function [11,12,13], possibly implying regulatory control.
Although regulation of CD8
+ T cells has also been described in
alloimmunity [14], the direct influence of human CD4
+ Tregs on
CD8
+ cytotoxicity and the mechanisms of this interaction have not
been well clarified. In human renal allograft biopsies in acute
rejection in which putatively regulatory Forkhead/winged-helix
protein 3 (FOXP3) staining cells have predominated clinically
favorable prognoses have been reported [15]. Similar findings have
been described in the urine ‘‘compartment’’ in such recipients [16].
Since many of the findings in animal models are not applicable
in humans and since many experiments cannot be performed in
the human, we have used ex vivo culture systems to analyze the role
of regulatory T cells on alloimmunity. We have previously
reported that increased numbers of human CD4
+CD127
2
CD25
+FOXP3
+ cells are generated after a 7 day bulk mixed
lymphocyte reaction (MLR) and that when isolated (MLR-Tregs)
and added as third components, these cells allospecifically
inhibited a primary MLR as well as caused increased percentages
of newly generated CD4
+CD127
2CD25
+FOXP3
+ T cells termed
‘‘regulation recruitment’’ [17]. In a clinical tolerance study, we
have observed that the percentages of CD4
+CD127
2CD25
high-
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+ cells increased by 10-fold from the pre-operative values
during the first 6 months and remained .4-fold even after 24
months in the peripheral blood mononuclear cells (PBMC) of
Human leukocyte antigen (HLA) -identical kidney recipients. This
protocol involved alemtuzumab induction, donor CD34
+ hema-
topoietic stem cell infusion, and Tacrolimus to Sirolimus
conversion followed by slow withdrawal of immunosuppression
[18]. In this study, when post-op recipient PBMC containing these
high percentages of putative Tregs were added as third component
modulators, they inhibited the donor-specific proliferation of
cryopreserved pre-op recipient CFSE-labeled PBMC responders,
as well as enhanced the newly generated CD4
+CD127
2CD25
high-
FOXP3
+ cells in the CFSE labeled proliferating responders
[17,18]. In the present report, ex vivo generated MLR-Tregs have
been tested as modulator cells for their effects in a modified Cell
Mediated Lympholysis (micro-CML)
51Chromium release assay to
measure CTL regulation. It was questioned whether these MLR-
Tregs could regulate the generation and cytotoxicity of CD8
+
CTL and whether this regulation had allospecificity. Additional
mechanisms of the CD4
+/CTL regulatory effect were probed by
experiments measuring MLR-Treg effects on CD8
+ proliferation,
and the expression of cytolytic, apoptotic and activation molecules.
Materials and Methods
Human subjects and HLA Typing
Peripheral blood mononuclear cells (PBMC) were obtained
from healthy volunteers that were HLA typed by the Northwest-
ern histocompatibility laboratory using molecular methods. They
were selected for this study to be HLA- A, B and DR mismatched
with each other. The research was conducted on these human
subjects with the approval of the Northwestern Institutional
Review Board. Informed written consent was obtained from each
human subject.
Generation of Tregs in MLR
MLR-Tregs were generated as we previously reported [17] and
as shown in the top portion of Figure 1. Briefly, PBMC were
isolated by Ficoll-Hypaque density gradient centrifugation and
40610
6 responder cells were stimulated with 40610
6 irradiated
(3000 R) stimulator cells in culture medium [NAB-CM; RPMI-
1640 supplemented with 2 mM L-glutamine, 10 mM HEPES,
100 U/ml Penicillin-Streptomycin (all from Mediatech, Mana-
ssas, VA) and 15% normal human AB serum (Gemini Bio-
Products, W. Sacramento, CA)] at 1610
6 cells/ml at 37uCi n5 %
CO2 in multiple T-75 flasks. After 7 days, the
CD4
+CD127
2CD25
+ cells were purified using the Treg isolation
kit and the AutoMACS (Miltenyi Biotech, Auburn, CA) as
previously described [17].
Immunophenotyping of MLR-Tregs
As previously described [19], immunophenotyping for surface
markers CD3, CD4, CD8, CD25 and CD127 was performed with
monoclonal antibodies directly conjugated with one of four
fluorochromes, that is, fluorescein isothiocyanate (FITC), phyco-
Figure 1. Flow diagram depicting the culture system for the generation of MLR-Tregs (step #1) and their utilization in various MLR,
micro- CML and flow cytometric assays (step #2).
doi:10.1371/journal.pone.0022450.g001
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(Beckman-Coulter, Miami, FL). Intracellular FOXP3 staining
was performed using PE-conjugated FOXP3 kits (eBiosciences,
San Diego, CA) following the manufacturer’s instructions.
Readings were performed in a 5-color FC500 flow cytometer
(Beckman Coulter), by analysis for 1610
5 cellular events. Isotype
controls were used to determine background fluorescence.
Suppression of MLR proliferation by MLR-Tregs
MLR-Tregs or autologous responder irradiated PBMC controls
were added as modulators (10,000, 2,000 and 400) to freshly
prepared MLRs in triplicates containing 1610
5 responder and
stimulator PBMC in 96-well U-bottom plates. These readout
MLRs for donor-specific suppression contained cells obtained
from the original fully HLA mismatched responder/stimulator
combination used in generating the MLR-Tregs. However, for
assessment of non-specific suppression in the readout MLR, the
irradiated stimulator PBMC used were from a different and fully
HLA mismatched (third party) individual than the one used in
generating the MLR-Tregs. After 7 days in culture, 1 uCi
3H-TdR
was added for 18 hrs and the cultures were harvested. Radioactive
incorporation was measured as CPM in a Perkin-Elmer
scintillation counter. The percentage of inhibition by the Tregs
was calculated using the formula: [12(CPM in presence of Treg
modulators) / (CPM in presence of control modulators)6100].
Cell subset isolation from PBMC
Purified CD8
+ T cells and CD4
+ T cells were isolated from fresh
PBMCs using CD8 microbeads or CD4 microbeads (Miltenyi
Biotech) respectively by positive selection according to the
manufacturer’s protocol. The purity was over 99% as estimated
by flow cytometric analysis. Non-T antigen presenting cells (APCs)
were isolated by depletion of CD2
+ cells from fresh PBMCs by
CD2 microbeads (Miltenyi Biotech) according to the manufactur-
er’s protocol. These were an admixture of cells with a purity of
non-T cells of over 96% as assessed by flow cytometric analysis.
Micro-Cell-mediated lympholysis (Micro-CML) [20]
Briefly, 1610
5 PBMC, 5610
4 purified CD8, 5610
4 purified
CD8 plus non-T ‘‘APCs’’ or 5610
4 purified CD8 plus purified
CD4
+ responder cells were respectively stimulated with 1610
5
irradiated PBMCs in mixed culture replicates of 10 in 96-well, U-
bottom plates at 0.2 ml/well in the absence or presence of 10 U/
ml recombinant interleukin-2. The proportion of CD4
+ or non-T
‘‘APC’’ added to the purified CD8
+ responders were equivalent to
that observed in the total PBMC of the individual blood donor.
After a 7 day culture period,
51chromium-labeled PHA blast target
cells (5610
3) were added to each mixed culture well. Four hours
later, 25 ml supernatants without cells were transferred to a
Lumaplate (Perkin-Elmer) and radioactivity was measured on a
TopCount (Perkin-Elmer). Cultures with stimulator cells plus
Figure 2. Purity and FOXP3 expression of MLR-Tregs. PBMCs from a healthy volunteer were stimulated with irradiated PBMC from an HLA fully
mismatched donor. After 7 days, the CD4
+CD127
2CD25
+ cells were isolated by the Treg isolation kit (methods). These cells were designated as MLR-
Tregs. The purity of the isolated cells was assessed for the indicated markers by flow cytometry. The gating strategy is indicated by arrows and title
headings on histograms. Thus, the viable cells (top left) were gated based on forward scatter and side scatter and then on CD4
+ cells (top middle)
followed by CD25
+ or CD25
high expression (top right). The FOXP3 and CD127 levels were then assessed on indicated gates (bottom). These dot plots
depict 1 example of .30 experiments performed in this report.
doi:10.1371/journal.pone.0022450.g002
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Spontaneous and maximum release (SR and MR) were deter-
mined by adding target cells to wells containing NAB-CM or 1%
Triton X-100, respectively. The data were expressed as follows: %
specific lysis=[(Mean CPM in sample)2(Mean CPM in NC) /
(Mean CPM in MR)2(Mean CPM in SR)]6100. For assessing
suppression, MLR-Tregs or irradiated autologous PBMC controls
were added as modulators at dilutions of 10,000, 2,000 or 400 cells
to the micro-CML wells at the time of mixed culture preparation
on day 0 (Figure 1). The percentage of inhibition of lysis by the
MLR-Tregs was calculated using the formula: [12(% Specific
Lysis in presence of Treg modulators) / (% Specific Lysis in
presence of control modulators)6100].
CFSE or PKH26 staining of responder cells
Responder PBMC or purified CD8
+ cells were labeled with the
green fluorescent dye carboxyfluorescein diacetate, succinimidyl
ester (CFSE) or red fluorescent dye PKH26 (both from Sigma-
Aldrich, St. Louis, MO), as per the manufacturer’s protocols. The
efficiency of labeling was determined before the cells were used in
experiments and was .95%. These labeled cells were used for
assessing the regulatory functions of MLR-Tregs in flow
cytometric analyses.
Flow Cytometry Analyses of purified CD8 cells regulated
by MLR-Tregs
10,000 MLR-Tregs or irradiated PBMC controls were added as
modulators to 5610
4 purified CD8 (CFSE or PKH26 labeled)
responders stimulated with 1610
5 irradiated PBMCs in 96-well, U-
bottom plates at 0.2 ml/well in the absence or presence of 10 U/ml
recombinant interleukin-2. After 7 days in culture, the cells were
harvested, like cultures combined and 4-color flow cytometry was
performed as above for cell surface expression with anti-human CD8-
ECD, anti-human CD28-PC5, anti-human CD25-PC7 (all from
Beckman-Coulter, Miami, FL) and anti-human FasL-FITC. Intra-
cellular expression with anti-human perforin-FITC and anti-human
granzyme B-FITC, (all from eBiosciences, San Diego, CA) was also
measured in multiple tubes as per the manufacturer’s instructions. In
Figure 3. The ability of MLR-Tregs to allospecifically suppress MLR proliferation. MLR-Tregs were added as modulators in descending
concentrations of 1610
4,2 610
3 or 0.4610
3 cells per well to 1610
5 fresh responding PBMC from the same individual as the one from whom
MLR-Tregs were generated (i.e., the responders were autologous to MLR-Tregs). These were stimulated with 1610
5 irradiated PBMC and 18-hour
3H-Thymidine incorporation assays were performed (as diagrammatically shown in Figure 1; step# 2, left) and the data are shown as: (A) CPM:
3H-
TdR uptake in MLR of the responder to the original stimulator used in generating the MLR-Tregs in the presence of the indicated number of
modulator cells. Note that inhibition by MLR-Treg modulators is demonstrated by the differences between modulator Treg points, (right side), vs.
fresh Ax (autologous irradiated PBMC) added as modulator controls (left side) (**=p,.01; n=10). (B) Percentage inhibition: The CPM values (from
A) were converted to percent inhibition (Tregs vs. Ax; see Methods for the formula) and allospecific vs. non-specific inhibition is shown. For
allospecific inhibition the stimulators were from the original stimulators used for generating MLR-Tregs and for non-specific inhibition the stimulator
PBMC were from a different totally HLA mismatched (third party) individual. Note the drastic decrease in the inhibitory effect by MLR-Tregs in the
non-specific culture combinations as the modulator cell concentrations decreased (**=p,0.01; n=5).
doi:10.1371/journal.pone.0022450.g003
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CD8
+ responder cells were labeled with PKH26. Isotype controls
were used to determine background fluorescence. The data were
acquired for 100,000 events in a 5-color FC500 flow cytometer and
analyzed using the CXP program (Beckman-Coulter).
Statistical Methods
Data were depicted as means 6 SD. Comparisons were
performed by using the paired Student t-test. Differences were
considered significant if P values were less than 0.05.
Results
Purity of CD4
+CD127
2CD25
+ T Cells generated in MLR
When respondingPBMCwerecultured for7 dayswithirradiated
HLA-A, B, DR mismatched stimulating PBMC, the generated
CD4
+CD127
2CD25
+ cells could be immunoselected (Methods and
step 1 of Figure 1) to be .90% CD4
+CD25
+ and .99%
CD127dim/
2. Of these .95% were FOXP3
+ (Figure 2). The
preparations were designated as MLR-Tregs. These were added as
third component modulators as described in the Methods section
and in the lower portions (Part #2) of the flow diagram in Figure 1.
MLR-Tregs suppressed MLR proliferation with
allospecificity
To test for their suppressive function, MLR-Tregs were added
as third component modulators at doses of 1610
4,2 610
3 and 400
cells to freshly prepared MLRs of responders and stimulators
(1610
5) both of which were also used in generating the MLR-
Tregs. Figure 3A demonstrates that proliferation in the MLR
assay was profoundly suppressed by these concentrations of
modulator MLR-Tregs. This is in contrast to control assays in
which fresh irradiated PBMC autologous with the original
responder were tested as modulators (p,0.01).
Figure 4. Regulatory effects of MLR-Tregs in micro-CML assays of responding whole PBMC. MLR-Tregs were added as modulators in
descending concentrations of 1610
4,2 610
3 or 0.4610
3 cells per well to 1610
5 fresh responding PBMC from the same individual as the one from
whom MLR-Tregs were generated. These were stimulated with 1610
5 irradiated allogeneic PBMC and 4-hour
51Cr release assays against target cells
from the stimulator were performed (as diagrammatically shown in Figure 1; step# 2, middle). The data are depicted as: (A) Percent specific lysis:
against the specific stimulator used both in MLR-Treg generation and the micro-CML readout. Similar to the data shown in Figure 3, the inhibitory
effects by MLR-Tregs are depicted by the points on the right, and the absence of inhibitory effects by modulator controls (Ax) is shown by points on
the left side of each graph (**=p,.01; n=10). (B) Percentage inhibition: The percent specific lysis values were converted to percent inhibition
(see Methods for this calculation). To test for specific inhibition, the stimulator/targets were from the original donor used for generating MLR-Tregs
and for non-specific inhibition stimulator/target cells were from a third party donor. Note that allospecificity of CTL regulation is demonstrated with
more significant inhibition at higher concentrations of MLR-Tregs in responses against stimulating cells from the original donor vs. those of the third
party donor (**=p,0.01; *=p,0.05; n=5).
doi:10.1371/journal.pone.0022450.g004
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assessed by using the original stimulators [used in generating the
MLR-Tregs (specific)] versus totally HLA-mismatched (third
party; non-specific) stimulators in the read-out MLRs. To account
for the variability in the strength of the proliferative responses
(CPM values) among individual experiments, the data were also
expressed as percent inhibition (Figure 3B). As is shown in
Figure 3B, specific inhibition was more potent than non-specific
inhibition, especially with the 2 lower modulator numbers tested
(p,0.01).
Allo-specific regulation by MLR-Tregs of the micro-CML
using whole PBMC responders
MLR-Tregs were then added as modulators to assays using
whole PBMC to generate CTL activity in the micro-CML. The
CTL responses with MLR-Treg modulators were sharply reduced
(inhibited), and in a dose dependent manner (Figure 4). This was
compared to adding autologous irradiated responder third
component control modulators which showed no inhibitory effect
(Ax, Figure 4A). Inhibition occurred with both 10,000 and 2,000
modulator cells/well (p,0.01) but was not as reproducible with
the lowest MLR-Treg modulator concentration (400 cells/well).
Regulation of the micro-CML by MLR-Tregs also showed
allospecificity. This was demonstrated by the use of original versus
third party stimulators. Inhibition was significantly stronger using
the original stimulators (p,0.01 and ,0.05 indicating specificity
using the highest and intermediate modulator MLR-Treg
concentrations respectively) (Figure 4B).
Lack of allospecificity of CTL regulation by MLR-Tregs if
purified CD8
+ cells were used as responders
It was questioned whether CD8
+ cells purified from PBMC
could be regulated by MLR-Tregs in generating CTL. Accord-
ingly, CD8
+ cells were immunoselected from whole blood and
were tested as responders in MLR-Treg modulated cultures. The
inhibition was similar to that of unpurified PBMC described
above, in that the CTL activity of purified CD8
+ cells was also
inhibited by MLR-Tregs when compared to control (Ax)
modulators (p,.01 at the highest and intermediate modulator
concentrations) (Figure 5A). However, in contrast with assays in
which non-purified PBMC were used as the responders, inhibition
of CD8
+ responders did not appear to be as prominently
allospecific. In these latter experiments (Figure 5B), the degree of
lysis inhibition appeared similar between allospecific and non-
Figure 5. Regulatory effects of MLR-Tregs in micro-CML assays of responding purified CD8
+ cells. Micro-CML inhibition assays were
performed as described in Figure 4, except that 5610
4 purified CD8
+ cells rather than whole PBMC (1610
5) were used as responders. The data are
depicted as: (A) Percent specific lysis: against the specific stimulator used both in MLR-Treg generation and the micro-CML readout. Similar to the
data in Figure 4A, the lysis of target cells was decreasingly inhibited by decreasing concentrations of MLR-Tregs (**=p,.01; n=6). (B) Percentage
inhibition: the percent specific lysis values were converted to percent inhibition. In contrast to the findings depicted in Figure 4B, inhibition of
purified responding CD8
+ CTL activity did not appear to be as clearly allospecific, i.e. there was a lack of significant differences between the points on
the right side vs the left side of each graph in the lower row (p.0.05; n=5).
doi:10.1371/journal.pone.0022450.g005
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MLR-Treg generation vs. third party stimulator/targets) (p.0.05).
These data suggest that the specificity of CTL regulation by MLR-
Tregs might be due to an indirect rather than a direct effect on the
CD8 responders.
Regulatory allospecificity of CTL reactivity by MLR-Tregs
requires cognate CD4
+ T cell recognition
We then questioned whether the loss of regulatory specificity
could be restored by adding back other PBMC components to the
purified responder CD8
+ cells. First, autologous ‘‘APCs’’ (see
Methods) were added back to these purified CD8
+ responding cells
in the MLR-Treg modulated cultures (Figure 6A). However, the
allospecificity of lysis inhibition could not be restored, i.e., the
regulation of lysis by MLR Tregs was the same using the original
stimulator/targets (specific) compared with third party (nonspecif-
ic) stimulator/targets (p.0.05) (Figure 6B).
In contrast, when purified autologous CD4
+ T cells were added
back to purified CD8
+ cells, not only did inhibition of CTL activity
by these MLR-Tregs occur (Figure 7A), but also the allospecificity
of CTL regulation was restored. This was demonstrated when
stimulator/target cells from original donors vs. third party donors
were compared (p,0.05 showing differences at the highest and
intermediate modulator concentrations, Figure 7B). These data
indicated that purified CD4
+ T cells appeared to play a necessary
role in the regulatory specificity of CTL activity by the MLR-
Tregs. As such, the MLR-Tregs required the presence of their
cognate CD4
+ T cells to restore/enhance regulation specific for
the original stimulator.
MLR-Tregs suppress the proliferation of purified CD8 cells
Purified CD8
+ responders were labeled with CFSE and
cultured with the original specific allogeneic stimulators and
with the decreasing concentrations of allospecific MLR-Treg
modulators. When followed-up in flow cytometry, these CD8
+
cells showed a lack of CFSE dilution with the higher
concentration of MLR-Treg modulators. This signified inhibition
of a proliferative response (Figure 8). This was in contrast with
CFSE dilution (proliferation, i.e. no inhibition) seen with the
(positive) controls cocultured with similar numbers of fresh
autologous irradiated cells. Thus CD8
+ proliferation was
profoundly inhibited by MLR-Tregs. Such inhibition of prolif-
Figure 6. MLR-Tregs non-specifically regulate cytotoxic activity in micro-CML generated by purified CD8
+ plus autologous non-T
‘‘APC’’ responders. Micro-CML inhibition assays were performed with purified CD8
+ responders as described in Fig. 5, but in presence of non-T
‘‘APCs’’ autologous to the responders, and the data are shown as: (A) Percent specific lysis: against the specific stimulator used both in MLR-Treg
generation and the micro-CML readout. The lysis of target cells was decreasingly inhibited by decreasing concentrations of modulating MLR-Tregs
(points on the right side) as opposed to none seen using control (Ax) modulators (points on the left side) (**=p,.01; n=10). (B) Percentage
inhibition: the percent specific lysis values were converted to percent inhibition. In contrast to the findings depicted in Figure 4B, using the original
vs third party stimulating cells, inhibition of CTL activity generated by purified CD8
+ plus non-T ‘‘APC’’ did not appear to be allospecific. Note the lack
of significant differences between the points on the right side vs the left side of each graph in the lower row (n=5).
doi:10.1371/journal.pone.0022450.g006
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+ responders
were used (Figure 9). This inhibition occurred either in the
presence or absence of IL2 (Figure 8) (n=3).
Inhibition of CTL differentiation and activation molecules
by MLR-Tregs
To further analyze the mechanism of CTL regulation mediated
by MLR-Tregs, the levels of effector molecules and activation
markers on CD8
+ responders reacting to the original specific
stimulator were assessed (Figure 9). Intracellular expression of the
cytolytic molecules Perforin-A and Granzyme B in the proliferating
CD8
+ responder cells in flow cytometry was found to be profoundly
inhibited in the presence of MLR-Tregs. Fas-ligand expression was
not affected (data not shown). The expression of the (membrane)
activation marker CD25 was also drastically inhibited (Figure 9).
Discussion
It has been proposed that regulation of CTL reactivity by
CD4
+CD127
2CD25
+FOXP3
+ Tregs may be a mechanism by
which anti-donor responses are controlled after organ transplan-
tation [4,21,22]. However, most of the recent studies performed to
analyze this, utilized non-allogeneic Treg generating conditions.
This has included anti-CD3/anti-CD28 antibody activation,
peptide pulsed dendritic cells [23,24,25,26] or exogenous addition
of cytokines such as TGF-b and IL-2 [23,24,25,26]. So as to more
closely approximate conditions of cellular alloimmunity in human
organ transplantation, we used whole PBMC in MLR to generate
such Tregs. These cells had the phenotypic hallmark of being
CD4
+CD127
2CD25
+FOXP3
+, defining regulatory T cells [17]
(Figure 2). When purified CD4
+CD127
2CD25
+FOXP3
+ cells
generated in MLR (designated MLR-Tregs) were added as
modulators into a primary readout MLR, they suppressed the
proliferative response in a dose dependent and allospecific manner
(Figure 3B), as in our previous report [17]. The present study has
been extended to analyze the regulatory effects of these MLR-
Tregs on cytotoxic alloreactivity and the mechanism of this action
using a micro-CML assay [20]. The lytic function of CTLs was
sharply inhibited by the presence of MLR-Tregs in a dose
dependent and alloantigen specific manner when whole PBMCs
were used as micro-CML responders (Figure 4A). Although the
majority of these cells were CD25
high (see Figure 1) they were not
Figure 7. MLR-Tregs allospecifically regulate cytotoxic activity in micro-CML generated by purified CD8
+ plus purified autologous
CD4
+ responders. Micro-CML inhibition assays were performed with purified CD8
+ responders as described in Figure 5, but in presence of purified
CD4
+ cells autologous to the responders; the data are depicted as: (A) Percent specific lysis: against the specific stimulator used both in MLR-Treg
generation and the micro-CML readout. The lysis of target cells was decreasingly inhibited by decreasing concentrations of modulating MLR-Tregs
(points on the right side) as opposed to none seen using control modulators (points on the left side) (**=p,.01; n=10). (B) Percentage
inhibition: the percent specific lysis values were converted to percent inhibition. Noteworthy is that in contrast with the findings depicted in
Figure 5B (but similar to those of Figure 4B), using the original vs third party stimulator/target cells, allospecific lytic inhibition was restored by using
purified CD8
+ to which purified autologous CD4
+ cells were added (*=p,0.05; **=p,0.01; n=5).
doi:10.1371/journal.pone.0022450.g007
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thymic derived ‘natural’ Tregs, because they were alloactivated, it
was not considered likely that they would express the ‘‘Helios’’
marker found in naı ¨ve thymic Tregs [27].
Camara [14] described that human naturally occurring
CD4
+CD25
+ regulatory T cells isolated from fresh PBMC could
impair CTL activity, somewhat analogous to the present report
using MLR generated CD4
+CD127
2CD25
+FOXP3
+ Tregs.
However, to our knowledge, the present study shows for the first
time that such MLR generated Tregs can regulate CTL reactivity
with donor allospecificity, more cogent information in human organ
transplantation. These MLR-Tregs appear to have acquired what
might be termed ‘‘regulatory memory’’ ex vivo, acting with more
potent suppression using the original stimulator. A recent report
by Peters et. al. [28] demonstrated that human naturally occurring
Tregs could be expanded ex vivo to acquire full antigen-specificity
when stimulated by HLA mismatched irradiated PBMCs in the
presence of IL-2 and IL-15. This specificity was detected by a
proliferation assay of CD4
+ cells. It was emphasized that primary
allogeneic stimulation was a prerequisite. This is consistent with
the present findings showing donor-specific regulation of CTL by
MLR-Tregs when whole PBMC were used to generate CTLs. It is
also consistent with the allospecific recruitment phenomenon
caused by MLR-Tregs on autologous MLR responding cells,
described in our previous report [17].
In the present study in order to explore the direct regulatory
effect on CD8
+ cells by MLR-Tregs, purified CD8
+ cells instead of
PBMCs were used as responders to generate CTLs in the presence
of IL-2 (10 U/ml). Suppression of lytic activity was still observed.
It was not eliminated in the presence of exogenous IL-2. This
supports recent studies demonstrating that addition of exogenous
IL-2 had no effect on Treg mediated suppression of mRNA
production in responder T cells [14]. However, unlike the
allospecific suppression of CTL reactivity by MLR-Tregs when
using PBMC as responders to generate CTLs, the regulatory
specificity (variably) disappeared when PBMCs responders were
replaced by purified CD8
+ cells to generate CTLs. Allospecific
regulation was reconstituted by addition of CD4
+ T cells
(Figure 7B) but not by Non-T ‘‘APCs’’ (Figure 5). This appeared
to indicate that MLR-Tregs would need (autologous) cognate
responding CD4
+ T cells present to exert their regulatory
allospecificity, but that non-allospecific suppression could occur
Figure 8. MLR-Tregs suppress purified CD8 allospecific proliferation. 5610
4 CFSE labeled purified CD8 cells were cultured with 1610
5
irradiated PBMC from the original stimulator (used in generating MLR-Tregs) together with indicated numbers of autologous MLR-Treg modulators or
autologous irradiated controls (Ax), either the presence (top row) or absence (bottom row) of IL-2 (10 U/ml). After 7 days in culture flow cytometric
assays were performed and the percentage of CFSE-diluted cells was estimated after gating on viable lymphocytes followed by CD8
+ cells. It was
observed that the irradiated stimulators and Ax died off by day 7 (not shown); even the few that remained were gated out on CFSE vs. CD8 density-
plot during the analysis. Note the increasing percentages of (CFSE diluted) proliferating cells with decreasing concentrations of the MLR-Treg
modulators. In the left column are depicted the results of negative control cultures (CD8 responders) in the absence of allogeneic stimulators or
modulators. The figure is representative of 3 such experiments. (**=p,0.01; n=3).
doi:10.1371/journal.pone.0022450.g008
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+ cells. In recent studies, CD4
+ T cells have
been shown to play a critical role in the CTL expansion and
differentiation [29,30,31,32]. In most experimental systems
analyzing the effect of Tregs in vitro, there is a requirement for
cell-cell contact for the regulatory effect occur [10,14,33,34,35].
Likewise, Tregs and effector CTLs have been observed to be in
close association with each other in a number of in vivo or in situ
studies [9,36]. We have actually performed transwell diffusion
chamber experiments to further pursue this point and found that
the cytotoxic regulatory effect was limited to direct cell-to-cell
contact between the CD4
+CD127
2CD25
+FOXP3
+ cells and the
CD8 cells generating cytotoxicity. If the putative Tregs were
enclosed in the upper chambers there was no regulatory effect seen
in the readout CD8 cells of the lower chambers (See Table S1).
Therefore, envisioning a requirement for cell-cell contact in the
present system also is consistent with these studies. Although CD8
+
cells plus ‘‘APCs’’ did not reconstitute the regulatory allospecificity
of MLR-Tregs, it is still possible that true APCs might play a
collaborative role in the regulation of CD4
+ T cells [37,38].
Finally, the present experiments demonstrate that MLR-Tregs
can suppress CD8
+ proliferation when stimulated by allogeneic
PBMCs, and that exogenous IL-2 (10 U/ml) did not block this
suppression. Moreover, the expression of the cytolytic molecules
perforin and granzyme B, but not FasL, in CD8 cells was reduced,
indicating possible inhibition of CD8
+ effector functions. The
expression of CD25 was decreased indicating that the activation of
CD8
+ cells was inhibited. Previous reports about these issues have
been somewhat conflicting. In a mouse tumor model, activated or
antigen-specific CD4
+ Tregs did not inhibit CD8 proliferation and
their differentiation to CTL, but blocked CTL killing [6,36].
However, in a human tumor model, intra-tumor Treg cells were
described inhibiting CD8
+ proliferation and granule production
[39]. In a mouse model CD4
+CD25
+ Tregs suppressed CD8
+
proliferation induced by both polyclonal and Ag-specific stimuli, in
Figure 9. MLR-Tregs inhibit the expression of perforin, granzyme B and CD25 on responding CD8
+ cells. 5610
4 PKH26 labeled purified
responder CD8 cells were cultured with the original stimulators (1610
5) used in generating MLR-Tregs, in the presence of 1610
4 autologous
modulator MLR-Tregs (right) vs. autologous modulator controls (Ax; middle). After 7 days in culture, the expression of intracellular Perforin-A,
Granzyme-B, and membrane CD25 was assessed by flow cytometry. The CD8
+ responder cells were gated and the PKH26
high non-proliferating and
PKH26-diluted proliferating cells were analyzed. It was observed that the irradiated stimulators and Ax died off by day 7 (not shown); even the few
that remained were gated out on CFSE vs. CD8 density-plot during the analysis. Note that there was a profound inhibition of both proliferation
(PKH26 dilution) and expression of Perforin-A, Granzyme-B and CD25 by MLR-Tregs. This experiment is representative of 4 similar ones. (**=p,0.01;
n=4).
doi:10.1371/journal.pone.0022450.g009
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and CD25 expression [40]. Similar findings were also reported in
human HCV and HIV infected patients [10,33,41]. In humans
CD4
+CD25
+ Tregs inhibited both CD8 proliferation and the
expression of perforin and granzyme B at the transcriptional level
[14]. These variable findings in diverse experimental models need
further clarification.
In conclusion, human CD4
+CD127
2CD25
+FOXP3
+ regulato-
ry T cells generated in MLR can inhibit CD8
+ CTL lytic function
both allospecifically and non-specifically. Regulatory allospecificity
appears to require the presence of cognate CD4
+ T cells. CTL
regulation appears to be mediated through impaired proliferation,
inhibited expression of the cytolytic molecules perforin and
granzyme B, and decreased CD25 expression. Speculatively, our
findings add support to the notion of utilizing such ex vivo
generated Tregs in clinical organ and tissue transplantation.
Supporting Information
Table S1 Assessment of cell-cell contact requirement for CTL
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(DOC)
Acknowledgments
This study was approved by Institutional Review Board of Northwestern
University, and the Jesse Brown VAMC.
Author Contributions
Conceived and designed the experiments: YY JM JRL ART JL XL JMM.
Performed the experiments: YY DC. Analyzed the data: YY JM ART DC
JMM. Wrote the paper: YY JM JRL ART JL XL JMM.
References
1. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory
T cells in immunological tolerance to self and non-self. Nature Immunology 6:
345–352.
2. Gorantla VS, Schneeberger S, Brandacher G, Sucher R, Zhang D, et al. (2010)
T regulatory cells and transplantation tolerance. Transplantation Reviews 24:
147–159.
3. Wood KJ, Sakaguchi S (2003) Regulatory T cells in transplantation tolerance.
Nature Reviews Immunology 3: 199–210.
4. Carvalho-Gaspar M, Jones ND, Luo S, Martin L, Brook MO, et al. (2008)
Location and time-dependent control of rejection by regulatory T cells
culminates in a failure to generate memory T cells. J Immunol 180: 6640–6648.
5. Lin CY, Graca L, Cobbold SP, Waldmann H (2002) Dominant transplantation
tolerance impairs CD8+ T cell function but not expansion. Nat Immunol 3:
1208–1213.
6. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, et al. (2005)
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through
TGF-beta signals in vivo. Proc Natl Acad Sci U S A 102: 419–424.
7. Billerbeck E, Bottler T, Thimme R (2007) Regulatory T cells in viral hepatitis.
World J Gastroenterol 13: 4858–4864.
8. Li S, Gowans EJ, Chougnet C, Plebanski M, Dittmer U (2008) Natural
regulatory T cells and persistent viral infection. J Virol 82: 21–30.
9. Sturm N, Thelu MA, Camous X, Dimitrov G, Ramzan M, et al. (2010)
Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis
C pathogenesis. J Hepatol 53: 25–35.
10. Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, et al. (2004) CD25(+)CD4(+)
regulatory T cells from the peripheral blood of asymptomatic HIV-infected
individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses
in vitro and are associated with favorable clinical markers of disease status. J Exp
Med 200: 331–343.
11. Graziotto R, Del Prete D, Rigotti P, Anglani F, Baldan N, et al. (2006) Perforin,
Granzyme B, and fas ligand for molecular diagnosis of acute renal-allograft
rejection: analyses on serial biopsies suggest methodological issues. Transplan-
tation 81: 1125–1132.
12. Miqueu P, Degauque N, Guillet M, Giral M, Ruiz C, et al. (2010) Analysis of the
peripheral T-cell repertoire in kidney transplant patients. European Journal of
Immunology 40: 3280–3290.
13. Satterwhite T, Chua M-S, Hsieh S-C, Chang S, Scandling J, et al. (2003)
Increased expression of cytotoxic effector molecules: different interpretations for
steroid-based and steroid-free immunosuppression. Pediatric Transplantation 7:
53–58.
14. Camara NO, Sebille F, Lechler RI (2003) Human CD4+CD25+ regulatory cells
have marked and sustained effects on CD8+ T cell activation. Eur J Immunol
33: 3473–3483.
15. Veronese F, Rotman S, Smith RN, Pelle TD, Farrell ML, et al. (2007)
Pathological and clinical correlates of FOXP3+ cells in renal allografts during
acute rejection. Am J Transplant 7: 914–922.
16. Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, et al. (2005)
Messenger RNA for FOXP3 in the urine of renal-allograft recipients.
N Engl J Med 353: 2342–2351.
17. Levitsky J, Miller J, Leventhal J, Huang X, Flaa C, et al. (2009) The human
‘‘Treg MLR’’: immune monitoring for FOXP3+ T regulatory cell generation.
Transplantation 88: 1303–1311.
18. Miller J, Leventhal J, Friedewald J, Levitsky J, charette j, et al. (2011) Enhanced
Immunoregulatory Profiles in HLA Identical Renal Transplant Recipients given
Donor Hematopoetic Stem Cells Alemtuzumab and Sirolimus followed by
Immunosuppression Withdrawal. American Journal of Transplantation 11: 92.
19. Mathew JM, Ciancio G, Burke GW, Garcia-Morales RO, Rosen A, et al. (2010)
Immune ‘‘tolerance profiles’’ in donor bone marrow infused kidney transplant
patients using multiple ex vivo functional assays. Human Immunology 71:
566–576.
20. Mathew JM, Blomberg B, Fuller L, Burke GW, Ciancio G, et al. (2003) A novel
micro-cell-mediated lympholytic assay for the evaluation of regulatory cells in
human alloreactive CTL responses. Journal of Immunological Methods 272:
67–80.
21. Cobbold SP (2002) T cell tolerance in transplantation: possibilities for
therapeutic intervention. Expert Opinion on Therapeutic Targets 6: 583–599.
22. Jones ND, Brook MO, Carvalho-Gaspar M, Luo S, Wood KJ (2010) Regulatory
T cells can prevent memory CD8+ T-cell-mediated rejection following
polymorphonuclear cell depletion. European Journal of Immunology 40:
3107–3116.
23. Chen W, Jin W, Hardegen N, Lei KJ, Li L, et al. (2003) Conversion of
peripheral CD4+CD252 naive T cells to CD4+CD25+ regulatory T cells by
TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875–1886.
24. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA (2007) IL-2 is essential for
TGF-beta to convert naive CD4+CD252 cells to CD25+Foxp3+ regulatory T
cells and for expansion of these cells. J Immunol 178: 2018–2027.
25. Luo X, Tarbell KV, Yang H, Pothoven K, Bailey SL, et al. (2007) Dendritic cells
with TGF-beta1 differentiate naive CD4+CD252 T cells into islet-protective
Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A 104: 2821–2826.
26. Selvaraj RK, Geiger TL (2007) A kinetic and dynamic analysis of Foxp3 induced
in T cells by TGF-beta. J Immunol 178: 7667–7677.
27. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, et al. (2010)
Expression of Helios, an Ikaros transcription factor family member, differentiates
thymic-derived from peripherally induced Foxp3+ T regulatory cells. Journal of
Immunology 184: 3433–3441.
28. Peters JH, Hilbrands LB, Koenen HJ, Joosten I (2008) Ex vivo generation of
human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells
for immunotherapy. PLoS One 3: e2233.
29. Buhlmann JE, Gonzalez M, Ginther B, Panoskaltsis-Mortari A, Blazar BR, et al.
(1999) Cutting edge: sustained expansion of CD8+ T cells requires CD154
expression by Th cells in acute graft versus host disease. J Immunol 162:
4373–4376.
30. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, et al. (2003)
CD4+ T cells are required for secondary expansion and memory in CD8+ T
lymphocytes. Nature 421: 852–856.
31. Williams MA, Tyznik AJ, Bevan MJ (2006) Interleukin-2 signals during priming
are required for secondary expansion of CD8+ memory T cells. Nature 441:
890–893.
32. Obar JJ, Molloy MJ, Jellison ER, Stoklasek TA, Zhang W, et al. (2010) CD4+ T
cell regulation of CD25 expression controls development of short-lived effector
CD8+ T cells in primary and secondary responses. Proc Natl Acad Sci U S A
107: 193–198.
33. Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, et al.
(2005) T cells with a CD4+CD25+ regulatory phenotype suppress in vitro
proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus
infection. J Virol 79: 7860–7867.
34. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA (2001) CD4+CD25high
regulatory cells in human peripheral blood. J Immunol 167: 1245–1253.
35. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC (2005) TCR
stimulation with modified anti-CD3 mAb expands CD8+ T cell population and
induces CD8+CD25+ Tregs. J Clin Invest 115: 2904–2913.
36. Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, et al. (2006)
Regulatory T cells reversibly suppress cytotoxic T cell function independent of
effector differentiation. Immunity 25: 129–141.
37. Lee BO, Hartson L, Randall TD (2003) CD40-deficient, influenza-specific CD8
memory T cells develop and function normally in a CD40-sufficient
environment. J Exp Med 198: 1759–1764.
38. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, et al. (2004)
Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity.
Nat Immunol 5: 1143–1148.
Cognate Treg Regulation of Human Allo-CTL
PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e2245039. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM (2006) Attenuation of
CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-
Hodgkin’s lymphoma. Cancer Res 66: 10145–10152.
40. Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T cell
activation by CD4+CD25+ immunoregulatory cells. J Immunol 167:
1137–1140.
41. Rushbrook SM, Ward SM, Unitt E, Vowler SL, Lucas M, et al. (2005)
Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells
during persistent hepatitis C virus infection. J Virol 79: 7852–7859.
Cognate Treg Regulation of Human Allo-CTL
PLoS ONE | www.plosone.org 12 July 2011 | Volume 6 | Issue 7 | e22450